July 21, 2022 | |
Name of listed company: Chugai Pharmaceutical Co., Ltd. | |
Code number: | 4519 (Prime Market of Tokyo Stock Exchange) |
Head office: | 1-1,Nihonbashi-Muromachi2-Chome,Chuo-ku, Tokyo |
President & CEO: | Osamu Okuda |
Inquiries to: | Toshiya Sasai |
Head of Corporate Communications Dept. | |
Tel: +81-(0)3-3273-0554 |
F. Hoffmann-La Roche Announces Half Year Results 2022
F. Hoffmann-La Roche Ltd. (hereafter "Roche") [Head Office: Basel, Switzerland. CEO: Severin Schwan] announced today its half year results 2022 (January 1 - June 30, 2022).
Roche owns 59.89% of Chugai's outstanding shares (61.14% of voting rights) as of the end of June 2022.
Its investor update and presentation materials can be found on its website (https://www.roche.com/).
Chugai's performance for the period of January 1 to June 30, 2022 is included in the announced Roche Group's results.
Investor Updates | Reporting |
###
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Chugai Pharmaceutical Co. Ltd. published this content on 21 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 July 2022 05:13:01 UTC.